Skip to main content

This job has expired

You will need to login before you can apply for a job.

Regional Business Director | Mid - Atlantic

Employer
Scilex Holding Company
Location
Philadelphia, PA
Start date
May 7, 2024

View more

Discipline
Information Technology, Business/Data Analytics
Required Education
Bachelors Degree
Position Type
Full time

Job Details

Salary Range: $176,000 - $198,500 

The pay range for this position is expected to be between $176,000 - $198,500/annually; however, the base pay offered may vary depending on multiple individualized factors, including market location, job-related knowledge, skills and experience.  The total compensation package for this position also includes medical benefits, 401(k) eligibility, vacation, sick time, and parental leave.  Additional details of participation in these benefit plans will be provided if an employee receives an offer of employment.   

If hired, employee will be in an “at-will position” and the Company reserves the right to modify base salary (as well as any other payment or compensation program) at any time, including reasons related to individual performance, Company or individual department/team performance, and market factors.  

Scilex Holding Company’s pay range data is provided in accordance with local state pay transparency regulations.  Scilex Holding Company may post different minimum wage ranges for permanent residency petitions pursuant to US Department of Labor requirements.   

Scilex Holding Company is committed to equal employment opportunities, and a workplace that embraces diversity and inclusion for qualified individuals of all backgrounds.   

About Scilex 

SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain.  We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. 

The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a marketed prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain. ZTlido® possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period.  Click here for ZTLido’s Important Safety Information and US Prescribing Information

We have acquired two FDA approved non-opioid pain products, GLOPERBA and ELYXYBTM, for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults. We launched ELYXYBTM in the U.S. in April 2023 and are planning to commercialize GLOPERBA in 2024. 

Our three product candidates are (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXATM”), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica and has received Fast Track Status from the FDA. Currently there is no FDA approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain (“LBP”) and has received Fast Track Status from the FDA; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.  If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in the United States. 

SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them the most. Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company. 

If you’re a high-energy, compassionate, and collaborative individual with a strong desire to make a difference in patient’s lives, we encourage you to consider joining the Scilex Holding team!  

Role and Responsibilities 

The Regional Business Director will be responsible for successfully hiring and leading a sales launch team, promoting non-opioid pain therapies. The RBD II will establish, lead, and develop a team of high-performing sales professionals that execute against the marketing plan and sales goals.  The RBD II must ensure that all activities fall within the corporate compliance guidelines and that representatives operate in a legal and ethical manner. Successful leadership, a record of hiring, coaching, developing, promoting, and retaining top talent within the span of control, and the ability to effectively manage the performance of the team. Provide clear direction and feedback of results achieved. Partner closely with the marketing teams and other sales channels to develop synergistic sales plans. 

  • Hire/Lead a region of 11-12 Sales Representatives
  • Responsible for the oversight of all aspects of sales, managed markets pull through, thought leader development, promotional programming, and budget management for your region
  • Coaching and mentoring to drive continuous improvement
  • Create and drive long-term strategy and short-term tactics to achieve business goals in a timely manner.
  • Develop regional business plans based on national sales goals, expectations, and available resources, including Regional and Territory strategies and tactics, as well as resource allocation.
  • Plan, design and implement territory alignment based on maximum ROI
  • Establish positive working relationships with all key customer segments (internal and external)
  • Conducts in-depth situation analysis to recognize areas for opportunity or improvement.
  • Communicate and collaborate with other Regional Business Directors, brand marketing, payer marketing, managed markets field teams, medical affairs and field teams, senior management and all other departments necessary to facilitate the achievement of sales objectives.
  • Be an expert in the clinical data, which affects current product promotion, disease state and market trends

Qualifications and Education Requirements  

  • Bachelor’s Degree required
  • 7+ years of Pharmaceutical sales experience required with at least 2 years in sales management
  • Experience in Pain or Neurology market preferred by not mandatory.
  • Experience managing through complex reimbursement environments
  • Documented Launch Experience
  • Start-up Experience preferred
  • Must be willing to travel overnight >50% of the week

Preferred Skills 

  • Award winner at representative and manager level (Documented)
  • Ability to engage; keen focus on the customer experience
  • Results-oriented professional who establishes & exceeds challenging goals while remaining flexible and responsive to the needs of others
  • Drives goals by creating strong links to other people’s priorities and point of view
  • Ability to identify and proactively drive the resolution of issues
  • Refuses to make assumptions; seeks to understand
  • Demonstrates agility to lead through challenges and opportunities of a growing company
  • Demonstrated a sense of urgency and pace
  • Ability to lead without authority through influence
  • Ability to adapt to a quick-changing, fast-paced, compliant environment
  • Develops self-managers through coaching and development
  • Strong business acumen
  • MS Office: specifically, PowerPoint and Excel

Established competencies to include:

Action Oriented, Business Acumen, Clinical Knowledge, Drive for Results, Influence, Interpersonal Skills, Managerial Courage; Negotiation, Problem Solving, Strategic Agility; Executive Presence.

Company

SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), majority-owned by Sorrento, is dedicated to the development and commercialization of non-opioid pain management products. We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.

The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a branded prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain.

Scilex’s SP-102 (10 mg dexamethasone sodium phosphate viscous gel injection), or SEMDEXA™, for the treatment of Lumbar Radicular Pain has completed enrollment in a Phase III clinical trial and has received Fast Track Status from the FDA. If approved by the FDA, the company expects SP-102 to be the first FDA-approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica, with the potential to replace 10 to 11 million off-label epidural steroid injections administered each year in the US.

SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them the most.

Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company.

Company info
Website
Phone
(650) 516-4310
Location
960 San Antonio Road
Palo Alto
California
94303
US

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert